Renaissance Capital logo

Autoimmune biotech Odyssey Therapeutics files for a $100 million IPO

January 17, 2025
Odyssey Therapeutics logo

Odyssey Therapeutics, a Phase 2-ready biotech developing precision therapies for autoimmune diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

Focused on patients suffering from autoimmune and inflammatory diseases, Odyssey is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its most advanced candidate, OD-07656, is a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2. The company plans to commence a Phase 2a monotherapy trial for ulcerative colitis in the 1Q25 and a Phase 2a combination trial with vedolizumab in the 1H26. Its pipeline also contains two preclinical programs: a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, and an agonistic protein therapeutic targeting tumor necrosis factor receptor 2.

The Boston, MA-based company was founded in 2021 and booked $3 million in collaboration revenue for the 12 months ended September 30, 2024. It plans to list on the Nasdaq under the symbol ODTX. Odyssey Therapeutics filed confidentially on October 7, 2024. Goldman Sachs, Jefferies, and TD Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.